Group 1 - The global in vitro diagnostics (IVD) market is projected to grow from $66.7 billion in 2018 to $186.1 billion by 2030, with a compound annual growth rate (CAGR) of 8.9% [1][2] - China's IVD industry has experienced rapid development and is transitioning into an upgrade and replacement phase, with diverse diagnostic technologies such as biochemical, immunological, POCT, molecular, and pathological diagnostics [2][3] - The market for immunodiagnostics in China is expected to grow from 37.3 billion yuan in 2021 to 50.3 billion yuan in 2023, with a CAGR of 16.13% [2] Group 2 - The biochemical diagnostics market in China is competitive, with domestic products holding over 70% market share, and the market size is projected to grow from 17.1 billion yuan in 2021 to 19.0 billion yuan in 2023, with a CAGR of 5.41% [3] - The POCT market in China is anticipated to grow from 11.2 billion yuan in 2021 to 16.0 billion yuan in 2023, with a CAGR of 19.52%, driven by the convenience of POCT applications and increased demand for rapid pathogen testing [3] - The molecular diagnostics market in China, while starting later, has reached a scale exceeding 10 billion yuan, supported by rising demand for precision medicine, technological advancements, and favorable national policies [3][4] Group 3 - The Chinese pathogen microbiological diagnostics market is projected to grow from 16.82 billion yuan in 2018 to 90.27 billion yuan by 2030, with a CAGR of 15.0% [4] - Companies to watch in the IVD sector include Mindray Medical (300760.SZ), New Industries (300832.SZ), Antu Bio (603658.SH), YHLO (688575.SH), Dirui Medical (300396.SZ), and Adeept Bio (300685.SZ) [4]

证券日报网讯12月22日，艾德生物（300685）在互动平台回答投资者提问时表示，公司高度重视股东回 报与市值管理，将持续优化经营策略，提升核心竞争力。 ...

Core Viewpoint - The company emphasizes its commitment to patient-centered approaches and focuses on the clinical needs in the field of tumor gene testing, particularly in drug companion diagnostics [1] Group 1 - The company has implemented a laboratory information management system in its laboratory [1] - The company is dedicated to deepening its expertise in tumor gene testing [1] - The company leverages strong bioinformatics algorithms to develop reagents, software, and supporting instruments [1] Group 2 - The company provides professional testing services and drug clinical research services [1]

格隆汇12月22日丨艾德生物(300685.SZ)在投资者互动平台表示，公司目前未开展基因芯片业务。 ...

格隆汇12月22日丨艾德生物(300685.SZ)在投资者互动平台表示，公司目前未开展基因芯片业务。 ...

Market Overview - The Shanghai Composite Index closed at 3884.93 points, with a slight decline of -0.11% [1] - The total trading volume of A-shares reached 1,198.5 billion yuan [1] Stocks with Death Cross - A total of 88 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between the 5-day and 10-day moving averages include: - Chuling Information (300250) with a distance of -1.55% [1] - Rongji Software (002474) with a distance of -1.40% [1] - Changyuan Donggu (603950) with a distance of -1.25% [1] Individual Stock Performance - Chuling Information (300250) saw a decline of -6.37% with a trading turnover rate of 11.94% [1] - Rongji Software (002474) decreased by -1.83% with a turnover rate of 10.53% [1] - Changyuan Donggu (603950) fell by -1.09% with a turnover rate of 0.41% [1] - Other notable declines include: - Shenhua A (000020) down -2.80% [1] - Sunshine Power (300274) down -3.41% [1] - Aide Biological (300685) down -3.43% [1] Additional Stock Data - Stocks with minor declines include: - Yitian Intelligent (300911) down -0.86% [2] - Hanrui (300618) down -1.70% [2] - Yinghe Technology (300457) down -3.03% [2] - Stocks with slight increases include: - Jinfatech (600143) up 0.67% [2] - Degoo (300950) up 0.13% [2]

（文章来源：证券日报） 证券日报网讯 12月12日晚间，艾德生物发布公告称，公司于近日收到欧洲专利局颁发的发明专利证 书，专利名称为一种用于核酸富集捕获的探针及设计方法。 ...

每经AI快讯，艾德生物（SZ 300685，收盘价：21.55元）12月12日晚间发布公告称，公司于近日收到欧 洲专利局颁发的发明专利证书。专利名称为"一种用于核酸富集捕获的探针及设计方法"。 2024年1至12月份，艾德生物的营业收入构成为：体外诊断行业占比100.0%。 每经头条（nbdtoutiao）——专访管涛：美国政府经济贸易政策正逐渐动摇美元本位国际货币体系，利 多因素下人民币汇率有可能破7 （记者 贾运可） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 截至发稿，艾德生物市值为84亿元。 ...

艾德生物12月12日公告，公司于近日收到欧洲专利局颁发的发明专利证书。发明专利名称：一种用于核 酸富集捕获的探针及设计方法，专利号：EP3480310，专利类型：发明专利，专利申请日：2017年6月 28日，专利权期限：自申请日起二十年。上述发明专利为公司自主研发，已在公司相关产品上应用。 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-068 厦门艾德生物医药科技股份有限公司 关于取得欧洲发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 专利类型：发明专利 专利申请日：2017年6月28日 专利权期限：自申请日起二十年 专利权人：厦门艾德生物医药科技股份有限公司 上述发明专利为公司自主研发，已在公司相关产品上应用。上述专利的取得 不会对公司近期生产经营产生重大影响，但有利于进一步完善公司知识产权保护 体系，充分发挥自主知识产权优势，促进技术创新，增强公司海外市场竞争力， 提升公司的综合实力。 厦门艾德生物医药科技股份有限公司 董 事 会 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"）于近 日收到欧洲专利局颁发的发明专利证书。具体情况如下： 发明专利名称：一种用于核酸富集捕获的探针及设计方法 专利号：EP3480310 2025 年 12 月 12 日 ...